12:00 AM
Mar 08, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Daptomycin: Began Phase III study

Cubist Pharmaceuticals Inc. (CBST), Cambridge, Mass.
Product: Daptomycin
Business: Infectious diseases
Therapeutic category: Bacterial infection
Target: Cell walls of gram positive bacteria
Description: Antibiotic that blocks lipotechoic acid utilization...

Read the full 121 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >